Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.
No takes yet. Share an insight, caveat, or question.
Schoretsanitis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: